Commentary|Videos|April 15, 2024
Next Steps With Pembrolizumab/Lenvatinib in Endometrial Cancer
Author(s)Christian Marth, MD, PhD
Christian Marth, MD, PhD, discusses next steps with pembrolizumab and lenvatinib for use in the advanced or recurrent endometrial cancer treatment paradigm.
Advertisement
Episodes in this series
Advertisement
Related to this article
CHMP has recommended EU approval of senaparib for advanced ovarian cancer based on FLAMES data.
Advertisement
Advertisement
Trending on OncLive
1
INBRX-106 Plus Pembrolizumab Improves Responses and PFS in First-Line PD-L1–Positive HNSCC
2
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
3
The OncFive: Top Oncology Articles for the Week of 9/27/2026
4
NDA Submission Is Initiated for Zipalertinib Plus Chemotherapy in Frontline EGFR Exon 20 Insertion+ NSCLC
5